

Q Korea's Hanmi pharmaceuticals struck a deal with Eli Lilly to develop and commercialize Hanmi's treatment for an auto immune disorder in a deal of upfront initial payment of \$50 million and future payment of up to \$640 million

Å?Â¢Å¢â??Â-Å?Â¢ National biotech firm, Green Cross Biotherapeutics, invested \$215 million in Canada to set up the first intravenous immunoglobulin and albumin manufacturing plant

Å?Â